The estimated Net Worth of Ventures V, Llc Versant Oph... is at least $9.5 Milhão dollars as of 3 June 2022. Ventures Oph owns over 750,000 units of Repare Therapeutics stock worth over $313,270 and over the last 4 years Ventures sold RPTX stock worth over $9,187,500.
Ventures has made over 2 trades of the Repare Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Ventures sold 750,000 units of RPTX stock worth $9,187,500 on 3 June 2022.
The largest trade Ventures's ever made was selling 750,000 units of Repare Therapeutics stock on 3 June 2022 worth over $9,187,500. On average, Ventures trades about 111,111 units every 79 days since 2020. As of 3 June 2022 Ventures still owns at least 111,484 units of Repare Therapeutics stock.
You can see the complete history of Ventures Oph stock trades at the bottom of the page.
Over the last 4 years, insiders at Repare Therapeutics have traded over $111,956,457 worth of Repare Therapeutics stock and bought 8,747,790 units worth $117,182,784 . The most active insiders traders include Partners L P/Ilbiotechnolog..., David P Bonita, eGroup, Llc Green Jeremy Red.... On average, Repare Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $446,135. The most recent stock trade was executed by Lloyd Mitchell Segal on 28 March 2024, trading 5,141 units of RPTX stock currently worth $23,751.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
Repare Therapeutics executives and other stock owners filed with the SEC include: